
Mylan Announces Partnership with Theravance to Develop an Investigational Treatment for COPD
Mylan announced a partnership with Theravance Biopharma to develop and commercialize TD-4208, a novel investigational COPD treatment.
Mylan announced that it has entered a partnership for a novel COPD treatment with
The treatment, which is a nebulized long-acting muscarinic antagonist (LAMA), showed positive results during Phase II studies resulting in FDA approval for the design of the Phase III program. The once a day, single-agent product will be developed for COPD, as well as other respiratory diseases.
Mylan will pay Theravance $15 million in cash with an additional $30 million in equity investment by purchasing newly issued ordinary shares at $18.92 per share. Theravance could also receive up to $220 million in sales milestones payments, with $175 million associated with TD-4208 monotherapy and $45 million for future potential combination products.
Umer Raffat of Evercore ISI said in an analyst note that there are several LAMAs on the market, however there aren’t any nebulized forms available. Nebulizers are designed for patients that may have difficulties using typical inhalation devices, such as the elderly or young children. Raffat continued by explaining that the introduction of this novel drug could be substantial. Utilization of the nebulized form of drugs is approximately 9–10%, with an existing hand-held LAMA (Spiriva) doing approximately $5 billion in sales. A potential competitor not yet on the market is
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.